Vanguard Portfolio Management
CSTL icon

Vanguard Portfolio Management’s Castle Biosciences CSTL Stock Holding History

Vanguard Portfolio Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1M Sell
840,785
-20,986
-2% -$467K ﹤0.01% 2000
2026
Q1 		$21.2M Buy
+861,771
New +$28.2M ﹤0.01% 1880

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Vanguard Portfolio Management's CSTL Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its Castle Biosciences (CSTL) stake by 2.4% in Q2 2026, selling an estimated $467K and leaving 840,785 shares worth $20.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2000.

Vanguard Portfolio Management first reported a position in CSTL in Q1 2026 and has held it in 2 quarters since. The position peaked at $21.2M in Q1 2026. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Vanguard Portfolio Management held 840,785 shares of Castle Biosciences worth $20.1M as of Q2 2026.
  • Vanguard Portfolio Management sold 20,986 Castle Biosciences shares in Q2 2026, an estimated $467K.
  • Castle Biosciences made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2000 holding.
  • Vanguard Portfolio Management first reported a position in Castle Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's Castle Biosciences position peaked at $21.2M in Q1 2026.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.